| Trial registration number
|
NCT04578158 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04578158
|
First author
Last imported at : April 24, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Prof. Dr. Ikram Din Ujjan
|
Contact
Last imported at : April 24, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
ikramujjan@lumhs.edu.pk
|
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
2020-10-08
|
Recruitment status
Last imported at : April 24, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Completed
|
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Feb. 5, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Open label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : April 16, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
- age ≥ 18 years of either gender
- confirmed sars-cov-2 infection by rt-pcr
- currently diagnosed with mild-to-moderate symptoms of covid-19 at home in
self-isolation within 3 days of sars-cov-2 infection.
- displaying typical symptoms of covid-19 such as a high temperature, a new, continuous
cough, a loss or change to sense of smell or taste
- patients who have signed informed consent.
|
Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
- patients with proven hypersensitivity or allergic reaction to quercetin
- manifest contrary will
|
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Liaquat University of Medical & Health Sciences
|
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Pakistan
|
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
Severe/critical disease at enrollment
|
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
7: Severe/critical disease at enrollment
|
Total sample size
Last imported at : April 24, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
152
|
primary outcome
Last imported at : Feb. 5, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Percentage of subjects with COVID-19 disease progression
|
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : April 16, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Phase 3
|
Arms
Last imported at : Feb. 5, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 1051, "treatment_name": "Quercetin", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
|